|
|
|
|
|
|
|
|
|
|
|
|
|
23.02.26 - 22:21
|
ProAssurance Reports Results for Fourth Quarter and Full-Year 2025 (Business Wire)
|
|
|
BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $33.4 million, or $0.64 per diluted share, and operating income(1) of $42.4 million, or $0.82 per diluted share, for the three months ended December 31, 2025. For the year ended December 31, 2025, net income was $50.9 million, or $0.99 per diluted share, and operating income was $83.9 million, or $1.62 per diluted share.
Highlights(2)
Operating performance continues to demonstrate progress toward premium rate levels appropriate for the challenging conditions in the medical professional liability and workers' compensation markets.
Net Income was impacted by non-operating items totaling $9.0 million and $32.9 million for the quarter and year ended December 31, 2025, respectively, which are discussed under “Reconciliation of Net Income (Loss) to Non-GAAP Operating Income (Loss).”
Consolidated net premiums w...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.25 - 22:21
|
ProAssurance Reports Results for Second Quarter 2025 (Business Wire)
|
|
|
BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical professional liability, today reported net income of $21.9 million, or $0.42 per diluted share, and operating income(1) of $26.8 million, or $0.52 per diluted share, for the three months ended June 30, 2025. For the six months ended June 30, 2025, net income was $16.1 million, or $0.31 per diluted share, and operating income was $33.6 million, or $0.65 per diluted share.
Second Quarter Highlights(2)
Second-quarter operating performance continues to demonstrate our continued progress toward premium rate levels appropriate for the challenging conditions in the medical professional liability and workers' compensation markets. Net results were impacted by non-operating items totaling $4.8 million, which are discussed under “Reconciliation of Net Income (Loss) to Non-GAAP Operating Income (Loss)” on page 7.
Stable net premiums written of $135.9 million for our ...
|
|
|
09.07.25 - 18:33
|
AM Best Affirms Credit Ratings of ProAssurance Group Members and ProAssurance Corporation (Business Wire)
|
|
|
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a+” (Excellent) of the members of ProAssurance Group. Concurrently, AM Best has affirmed the Long-Term ICR of “bbb+” (Good) and the indicative Long-Term Issue Credit Ratings (Long-Term IRs) of ProAssurance Corporation (PRA) (headquartered in Birmingham, AL). The outlook of these Credit Ratings (ratings) is stable. All companies are indirect subsidiaries of PRA. (See below for a detailed listing of subsidiaries and indicative Long-Term IRs.)
The ratings of ProAssurance Group reflect its balance sheet strength, which AM Best assesses as strongest, as well as its adequate operating performance, favorable business profile and appropriate enterprise risk management (ERM).
The group's balance sheet strength assessment continues to be at the strongest level, with risk-adjusted capitalization, as measured by Best's Capital Adequ...
|
|
|
07.07.25 - 22:21
|
The Doctors Company and ProAssurance Announce Early Termination of the Hart-Scott-Rodino Waiting Period (Business Wire)
|
|
|
NAPA, Calif. & BIRMINGHAM, Ala.--(BUSINESS WIRE)--The Doctors Company, the nation's largest physician-owned medical malpractice insurer, and ProAssurance Corporation (NYSE: PRA), an industry-leading specialty insurer with extensive expertise in medical liability, products liability for medical technology and life sciences, and workers' compensation insurance, announced today that on July 2, 2025, the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to the pending acquisition of ProAssurance by The Doctors Company.
The termination of the waiting period under the HSR Act satisfies one of the conditions for the closing of the pending acquisition, which is expected to be completed in the first half of 2026, but which remains subject to other customary closing conditions, including receipt of the remaining regulatory approvals. The Doctors Company and ProAssurance will continue to oper...
|
|
|
|
|
24.06.25 - 22:18
|
ProAssurance Stockholders Approve Its Proposed Acquisition by The Doctors Company (Business Wire)
|
|
|
BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance Corporation (NYSE: PRA) today announced that stockholders have voted overwhelmingly to approve its proposed acquisition by The Doctors Company. More than 99% of shares voted (including abstentions) were in favor of the proposal to approve the acquisition agreement.
The transaction remains subject to the receipt of regulatory approvals and other customary closing conditions and is expected to close in the first half of 2026. Required regulatory approvals include the expiration or early termination of the waiting period (and any extension thereof) applicable to the consummation of the merger under the Hart-Scott-Rodino Act as well as approvals by the insurance regulators in the domicile states of ProAssurance insurance subsidiaries. The transaction is not subject to a financing condition. Upon completion of the transaction, ProAssurance's common stock will no longer be listed on the New York Stock Exchange, and ProAssurance will become a wholly owned subsidia...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
